Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Weiss, J. Freiman, S. Kweder, L. Diehl, J. Byrd (1998)
Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 5
G. Berchem, S. Dewilde, P. Mahassen (2009)
A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg, 1
A. Giagounidis, S. Haase, U. Germing, M. Heinsch, C. Aul (2005)
Autoimmune Disorders in Two Patients with Myelodysplastic Syndrome and 5q DeletionActa Haematologica, 113
Wanling Sun, L. Köck, A. Walder, M. Erdel, S. Kilga-Nogler, H. Schennach, M. Fiegl (2010)
Successful treatment of MDS with lenalidomide, complicated by transient autoimmune hemolysisAnnals of Hematology, 89
Milena Elimelakh, V. Dayton, Katharine Park, A. Gruessner, D. Sutherland, R. Howe, M. Reding, T. Eastlund, J. Burik, T. Singleton, R. Gruessner, N. Key (2007)
Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients.Haematologica, 92 8
S. Faderl, K. Rai, J. Gribben, J. Byrd, I. Flinn, S. O'brien, S. Sheng, D. Esseltine, M. Keating (2006)
Phase II study of single‐agent bortezomib for the treatment of patients with fludarabine‐refractory B‐cell chronic lymphocytic leukemiaCancer, 107
O. Lambotte, M. Gelu-Simeon, G. Maigné, R. Kotb, C. Buffet, J. Delfraissy, C. Goujard (2005)
Pegylated interferon alpha-2a-associated life-threatening Evans' syndrome in a patient with chronic hepatitis C.The Journal of infection, 51 3
T. Robak (2004)
Monoclonal antibodies in the treatment of autoimmune cytopeniasEuropean Journal of Haematology, 72
S. Sacchi, H. Kantarjian, S. O’Brien, Philip Cohen, S. Pierce, M. Talpaz (1995)
Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 9
S. Kako, Y. Kanda, K. Oshima, Nahoko Nishimoto, Hiroyuki Sato, Takuro Watanabe, N. Hosoya, T. Motokura, S. Miyakoshi, S. Taniguchi, A. Kamijo, Koki Takahashi, S. Chiba, M. Kurokawa (2008)
Late onset of autoimmune hemolytic anemia and pure red cell aplasia after allogeneic hematopoietic stem cell transplantation using in vivo alemtuzumabAmerican Journal of Hematology, 83
M. Razaq, Srisha Perumandla, N. Mankan, S. Sridhar, J. Sanmugarajah, G. Fernandez, S. Hussain (2006)
Hairy cell leukemia variant transforming into aggressive lymphoma with prostatic involvement in a patient with polycythemia vera.Leukemia & lymphoma, 47 4
M. Novaretti, C. Sopelete, E. Velloso, Martin-Crespo Rosa, P. Dorlhiac-Llacer, D. Chamone (2001)
Immunohematological Findings in Myelodysplastic SyndromeActa Haematologica, 105
M. Fiegl, A. Falkner, G. Hopfinger, S. Brugger, A. Zabernigg, F. Bauer, F. Haslbauer, Dita Demirtas, Peter Grossschmidt, G. Tatzreiter, G. Gastl, R. Greil (2006)
Routine clinical use of alemtuzumab in patients with heavily pretreated B‐cell chronic lymphocytic leukemiaCancer, 107
K. Takase, T. Nakano, M. Hamada, K. Shiraki, Y. Oohashi, Takayuki Kihira, Y. Tameda (1995)
Hemolytic anemia provoked by recombinant alpha-interferonJournal of Gastroenterology, 30
Marcia Novaretti, G. Fonseca, M. Conchon, P. Dorlhiac-Llacer, Dalton Chamone (2003)
First case of immune‐mediated haemolytic anaemia associated to imatinib mesylateEuropean Journal of Haematology, 71
E. Jourdan, D. Topart, B. Richard, J. Jourdan, A. Sotto (2003)
Severe Autoimmune Hemolytic Anemia Following Rituximab Therapy in a Patient with a Lymphoproliferative DisorderLeukemia & Lymphoma, 44
K Galesic, B Bozic, I Racic (2006)
Thrombotic microangiopathy associated with σ-interferon therapy for chronic myeloid leukemiaNephrology, 11
D. Wolf (2009)
IMiDs induce pleiotropic anti-cancer effectsmemo - Magazine of European Medical Oncology, 2
Cristiana Cauli, G. Serra, L. Chessa, C. Balestrieri, Rosetta Scioscia, M. Lai, P. Farci (2006)
Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin.Haematologica, 91 6 Suppl
KRESIMIR Galešić, B. Božić, I. Račić, M. Ščukanec-Špoljar (2006)
Thrombotic microangiopathy associated with α‐interferon therapy for chronic myeloid leukaemia (Case Report)Nephrology, 11
R. Jain, P. Mathew, C. Wood, N. Tannir (2008)
Sunitinib-induced acute hemolysis without hypertension: a case report.Clinical genitourinary cancer, 6 2
K. Darabi, Shailaja Kantamnei, P. Wiernik (2006)
Lenalidomide-induced warm autoimmune hemolytic anemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 35
SK Ramamoorthy, M Marangolo, E Durrant (2006)
Unusual reaction to Rituximab with intra-vascular hemolysis, rhabdomyolysis, renal failure and bone marrow necrosisLeuk Lymphoma, 47
Joshua Ruch, B. McMahon, G. Ramsey, H. Kwaan (2009)
Catastrophic multiple organ ischemia due to an anti‐Pr cold agglutinin developing in a patient with mixed cryoglobulinemia after treatment with rituximabAmerican Journal of Hematology, 84
A. List, S. Kurtin, D. Roe, Andrew Buresh, D. Mahadevan, D. Fuchs, L. Rimsza, R. Heaton, R. Knight, J. Zeldis (2005)
Efficacy of lenalidomide in myelodysplastic syndromes.The New England journal of medicine, 352 6
C. Frangié, C. Lefaucheur, J. Medioni, C. Jacquot, G. Hill, D. Nochy (2007)
Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.The Lancet. Oncology, 8 2
J. Arriba, C. Nerín, E. García, L. Gómez-Aldaraví, B. Vila (2003)
Severe hemolytic anemia and skin reaction in a patient treated with imatinib.Annals of oncology : official journal of the European Society for Medical Oncology, 14 6
G. Borthakur, S. O'brien, W. Wierda, D. Thomas, J. Cortes, F. Giles, H. Kantarjian, S. Lerner, M. Keating (2007)
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab – incidence and predictorsBritish Journal of Haematology, 136
V. Eremina, J. Jefferson, J. Kowalewska, H. Hochster, M. Haas, J. Weisstuch, C. Richardson, J. Kopp, M. Kabir, P. Backx, H. Gerber, N. Ferrara, L. Barisoni, C. Alpers, S. Quaggin (2008)
VEGF inhibition and renal thrombotic microangiopathy.The New England journal of medicine, 358 11
W. Wierda, T. Kipps, M. Keating, Jennifer Brown, J. Gribben, Mary Browning, L. Rassenti, Andrew Greaves, D. Neuberg, S. O'brien (2006)
Self-Administered, Subcutaneous (SQ) Alemtuzumab To Eliminate Residual Disease in Patients (pts) with CLL.Blood, 108
In the last decade, many novel immunomodulating therapies and “biologicals”, usually acting as signal transduction inhibitors, came into routine therapy in cancer. Mostly, these substances are well tolerated, and there is a typical spectrum of common side effects to be considered with these therapies. A rather rarely seen toxic effect associated with the administration of these agents is haemolytic anaemia (HA). Here, we shortly summarize current knowledge on HA potentially triggered by these substances. Furthermore, an impressive case of myelodysplastic syndrome with 5q deletion which received lenalidomide and developed autoimmune haemolytic anaemia (AIHA) is presented.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Apr 14, 2010
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.